应用由乳化-扩散方法制备的功能PLGA纳米颗粒的药物发送系统(英文)

Drug delivery system using functional PLGA nanoparticle prepared by emulsification-diffusion method

运用功能纳米颗粒的药物发送系统是一种具有发展前景的途径,因为它减少了副反应并减轻病痛 Poly(D,L lactide co glycolide)(PLGA)纳米颗粒的尺寸是80nm,它的制备是通过乳化扩散方法,并应用Poloxamer188作为稳定剂 所制备的纳米颗粒具有疏水核作为药物的载体,而其冠状亲水表面可避免形成网状内皮系统(RES) 作为生物医学应用的第一个例子是PLAG纳米颗粒包含雌激素,它对于受到意外伤害而抑制不安情绪具有局限性 研究指出:局部地发送具有雌激素的PLGA纳米颗粒将激烈减少新内膜的形成程度 其次是应用经过修改的PLAG纳米颗粒发送系统专用于骨治疗的药已经实现,它与骨有高度的相似 已经证明:与双磷酸(bisphosphonate)相结合的PLGA纳米颗粒,参入到鼠的静脉内之后。

Drug delivery system using functional nanoparticle is a promising way for the reduction of side effects and the sustained release. Poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles with size 80 nm were prepared through emulsification-diffusion method using Poloxamer 188 as a stabilizer. The prepared nanoparticles have the hydrophobic core for drug loading and the hydrophilic surface corona for avoidance of reticuloendocellial system (RES). First example of biomedical applications is the localization of PLGA nanoparticle containing estrogen for the inhibition of restenosis after balloon injury. In vivo study demonstrated that locally delivered PLGA nanoparticles with estrogen drastically decrease the degree of neointimal formation. Secondly, bone-specific drug delivery was carried out using PLGA nanoparticles modified with alendronate which have a high affinity to bone. It was shown that PLGA nanoparticles conjugated with bisphosphonate were accumulated into bone after intravenous administration into rats.